Optimized cocktail of 90Y/177Lu for radionuclide therapy of neuroendocrine tumors of various sizes: a simulation study

被引:1
|
作者
Peer-Firozjaei, Milad [1 ]
Tajik-Mansoury, Mohammad Ali [1 ,2 ]
Geramifar, Parham [3 ]
Ghorbani, Raheb [4 ]
Zarifi, Shiva [1 ]
Miller, Cassandra [5 ,6 ]
Rahmim, Arman [5 ,6 ]
机构
[1] Semnan Univ Med Sci, Fac Med, Dept Med Phys, Semnan 1985717443, Iran
[2] Shahid Beheshti Univ Med Sci SBMU, Sch Med, Dept Biomed Engn & Med Phys, Tehran, Iran
[3] Univ Tehran Med Sci, Shariati Hosp, Res Ctr Nucl Med, Nucl Med Dept, Tehran, Iran
[4] Semnan Univ Med Sci, Dept Epidemiol & Biostat, Fac Med, Social Determinants Hlth Res Ctr, Semnan, Iran
[5] BC Canc Res Inst, Dept Integrat Oncol, Vancouver, BC, Canada
[6] Univ British Columbia, Dept Phys & Astron, Vancouver, BC, Canada
关键词
radioisotope cocktail; tumor dosimetry; Lu-177; Y-90; DOSIMETRY; RADIOTHERAPY;
D O I
10.1097/MNM.0000000000001546
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background and objectives There is significant interest and potential in the treatment of neuroendocrine tumors via peptide receptor radionuclide therapy (PRRT) using one or both of Y-90 and Lu-177-labeled peptides. Given the presence of different tumor sizes in patients and differing radionuclide dose delivery properties, the present study aims to use Monte Carlo simulations to estimate S-values to spherical tumors of various sizes with Y-90 and Lu-177 separately and in combination. The goal is to determine ratios of Y-90 to Lu-177 that result in the largest absorbed doses per decay of the radionuclides and the most suitable dose profiles to treat tumors of specific sizes. Material and methods Particle transfer calculations and simulations were performed using the Monte Carlo GATE simulation software. Spherical tumors of different sizes, ranging from 0.5 to 20 mm in radius, were designed. Activities of Lu-177 and Y-90, individually and in combination, were homogeneously placed within the total volume of the tumors. We determined the S-values to the tumors, and to the external volume outside of the tumors (cross-dose) which was used to approximate background tissue. The dose profiles were obtained for each of the different tumor sizes, and the uniformity of dose within each tumor was calculated. Results For all tumor sizes, the self-dose and cross-dose per decay from Y-90 were higher than that from Lu-177. We observed that Lu-177 had the most uniform dose distribution within tumors with radii less than 5 mm. For tumors greater than 5 mm in radius, a ratio of 25% Y-90 to 75% Lu-177 resulted in the most uniform doses. When the ratio of Lu-177 to Y-90 was smaller, the uniformity improved more with increasing tumor size. The cross-dose stayed approximately constant for tumors larger than 15 mm for all ratios of Lu-177 to Y-90. Finally, as the size of the tumor increased, differences in the S-values between different ratios of Lu-177 to Y-90 decreased. Conclusion Our work showed that to achieve a more uniform dose distribution within the tumor, Lu-177 alone is more effective for small tumors. For medium and large tumors, a ratio of Y-90 to Lu-177 with more or less Lu-177, respectively, is recommended.
引用
收藏
页码:646 / 655
页数:10
相关论文
共 50 条
  • [1] Comparative evaluation of radionuclide therapy using 90Y and 177Lu
    Hanaoka, Hirofumi
    Hashimoto, Kazuyuki
    Watanabe, Satoshi
    Matsumoto, Shojiro
    Sakashita, Tetsuya
    Watanabe, Shigeki
    Ishioka, Noriko S.
    Endo, Keigo
    ANNALS OF NUCLEAR MEDICINE, 2023, 37 (01) : 52 - 59
  • [2] Comparative evaluation of radionuclide therapy using 90Y and 177Lu
    Hirofumi Hanaoka
    Kazuyuki Hashimoto
    Satoshi Watanabe
    Shojiro Matsumoto
    Tetsuya Sakashita
    Shigeki Watanabe
    Noriko S. Ishioka
    Keigo Endo
    Annals of Nuclear Medicine, 2023, 37 : 52 - 59
  • [3] Quantitative Imaging of 177Lu in the Presence of 90Y for Peptide Receptor Radionuclide Therapy: A Simulation Study
    Miller, C.
    Rahmim, A.
    Uribe-munoz, C.
    Celler, A.
    MEDICAL PHYSICS, 2020, 47 (06) : E550 - E550
  • [4] Quantitative SPECT/CT reconstruction for 177Lu and 177Lu/90Y targeted radionuclide therapies
    Shcherbinin, S.
    Piwowarska-Bilska, H.
    Celler, A.
    Birkenfeld, B.
    PHYSICS IN MEDICINE AND BIOLOGY, 2012, 57 (18): : 5733 - 5747
  • [5] Optimized Combination Therapy Applied to 90Y and 177Lu Peptide Receptor Radionuclide Therapy (PRRT) Based on Tumor Size Distribution
    Hobbs, R. F.
    Sgouros, G.
    Frey, E. C.
    Wahl, R. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S306 - S306
  • [6] 177Lu SPECT imaging in the presence of 90Y: does 90Y degrade image quantification? a simulation study
    Miller, Cassandra
    Uribe, Carlos
    Hou, Xinchi
    Rahmim, Arman
    Celler, Anna
    BIOMEDICAL PHYSICS & ENGINEERING EXPRESS, 2023, 9 (04)
  • [7] Clinical peptide receptor radionuclide therapy: Kit preparation of 90Y, 177Lu, and 111In DOTATATE
    Ballinger, J. R.
    Tan, Y.
    Allen, S. J.
    Lewington, V. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S425 - S425
  • [8] 177Lu/90Y-SSTR Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumor Cardiac Metastases
    Zhang, Jingjing
    Jakobsson, Vivianne
    Chen, Xiaoyuan
    Baum, Richard P.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [9] Polish Multicenter Experience with Tandem Peptide Receptor Radionuclide Therapy Using 90Y/177Lu-DOTATATE in Neuroendocrine Tumors
    Kunikowska, J.
    Zemczak, A.
    Kolodziej, M.
    Gut, P.
    Lon, I
    Pawlak, D.
    Mikolajczak, R.
    Kaminski, G.
    Ruchala, M.
    Kos-Kudla, B.
    Krolicki, L.
    NEUROENDOCRINOLOGY, 2019, 108 : 216 - 216
  • [10] Personalized, dosimetry-based PRRT therapy in patients with neuroendocrine tumors using [177Lu]Lu-DOTA-TATE or [177Lu]Lu/[90Y]Y-DOTA-TATE mixture - the initial results of DUONEN multicenter study
    Opalinska, M.
    Kaminski, G.
    Dedecjus, M.
    Kowalska, A.
    Kolodziej, M.
    Saracyn, M.
    Gasior-Perczak, D.
    Lenda-Tracz, W.
    Sowa-Staszczak, A.
    Borkowska, A.
    Budzynska, A.
    Kubik, A.
    Chalewska, W.
    Kacperski, K.
    Szubstarska, P.
    Garnuszek, P.
    Mikolajczak, R.
    Hubalewska-Dydejczyk, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S314 - S314